TruSight Oncology 500 Portfolio

TruSight Oncology 500 Assay

Now with HRD* *Not available in Japan

Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).

TruSight Oncology 500 High-Throughput Assay

Now offered on NovaSeq X Series

Batch up to 192 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA v2 Assay

Now offered on NovaSeq X Series

Analyze circulating tumor DNA (ctDNA) from blood plasma with a more sensitive and streamlined assay in <4 days with automation-friendly options.

TruSight Oncology 500 portfolio brochure

This brochure provides an overview of the TSO 500 product portfolio. You'll learn about Its broad coverage, integrated workflows, automation capabilities, easy-to-use data analysis and more. Take cancer from uncertainty to insight with streamlined solutions enabling high-quality cmprehensive genomic profiling.​

Download TSO 500 portfolio brochure​

aThe NovaSeq X Series and the NovaSeq 6000Dx System (in RUO mode) both require a separate, stand-alone DRAGEN server for secondary analysis.

bComing soon in 2024.

Pan-Cancer biomarkers

Detection of currently relevant DNA & RNA* variants for multiple types of solid tumors. Some key biomarkers include:
Pan-cancer: BRAFNTRK1 NTRK2 NTRK3RET MSI TMB
Genes with biomarkers of significance Genes with biomarkers of potential significance
breast cancer Breast BRCA1 BRCA2 ERBB2 ESR1 PALB2 PIK3CA       180
colorectal cancer Colorectal ERBB2 KRAS NRAS             166
bone cancer Bone EGFR ERG ETV1 ETV4 EWSR1 FEV FLI1 FUS H3F3A 140
HEY1 IDH1 MDM2 NCOA2 SMARCB1        
lung cancer Lung ALK EGFR ERBB2 KRAS MET NUTM1 ROS1     223
melanoma cancer Melanoma KIT NRAS ROS1             172
ovarian cancer Ovarian BRCA1 BRCA2 FOXL2             149
cns cancer CNS APC ATRX CDKN2A CDKN2B EGFR H3F3A HIST1H3B HIST1H3C IDH1 140
IDH2 MYCN PTCH1 RELA TERT TP53      
prostate cancer Prostate AR ATM BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2 151
FANCL FGFR2 FGFR3 PALB2 RAD51B RAD51C RAD51D RAD54L  
thyroid cancer Thyroid HRAS KRAS NRAS RET TERT         165
uterine cancer Uterine & cervical BRCA2 EPC1 ERBB2 ESR1 FOXO1 GREB1 JAZF1 NCOA2 NCOA3 138
NUTM2A NUTM2B PAX3 PAX7 PHF1 POLE SMARCA4 SUZ12 TP53
YWHAE                
other solid cancer tumors Other Solid Tumors ALK APC ARID1A ASPSCR1 ATF1 ATIC BAP1 BCOR BRCA1 152
BRCA2 CAMTA1 CARS CCNB2 CDK4 CDKN2A CIC CITED2 CLTC
COL1A1 COL6A3 CREB1 CREB3L1 CREB3L2 CSF1 CTNNB1 DDIT3 DDX3X
DNAJB1 DUX4 EED EGFR ERBB2 ERG ETV1 ETV4 ETV6
EWSR1 FEV FGFR2 FGFR3 FLI1 FOXL2 FOXO1 FOXO4 FUS
GLI1 HEY1 HGF HMGA2 IDH1 KRAS LEUTX MAML3 MDM2
MYB MYOD1 NAB2 NCOA2 NF1 NFATC2 NFIB NR4A3 NRAS
NUTMI NUTM2A NUTM2B PALB2 PATZ1 PAX3 PAX7 PDGFB PDGFRA
PRKACA PRKD1 RANBP2 ROS1 SDHA SDHB SDHC SDHD SMARCB1
SS18 SSX1 SSX2 SSX4 STAT6 SUZ12 TAF15 TCF12 TERT
TFE3 TFEB TFG TP53 TPM3 TPM4 TRAF7 TSPAN31 VGLL2
WT1 WWTR1 YAP1 YWHAE ZC3H7B        

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

* RNA variants only called from TSO 500 and TSO 500 HT assays.

The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Illumina NGS Methods Guide

Analytical evaluation guidance

The TruSight Oncology 500 analytical guidance expedites implementation with recommendations intended to align with the latest industry standards and best practices.

View guidance

Have questions about our products? Connect with an Illumina representative.